首页>
外国专利>
USE OF TIMP-1 AS A BIOMARKER IN THE EGF-RECEPTOR INHIBITOR TREATMENT OF METASTATIC COLORECTAL CANCER
USE OF TIMP-1 AS A BIOMARKER IN THE EGF-RECEPTOR INHIBITOR TREATMENT OF METASTATIC COLORECTAL CANCER
展开▼
机译：TIMP-1作为生物标记物在转移性大肠癌EGF受体抑制剂治疗中的应用
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention concerns the provision of biomarkers, in particular, TIMP-1 and RAS as biomarkers for the selection of patients in the treatment and prognosis of cancer, such as e.g. metastatic colorectal cancer (mCRC). The present invention also provides methods of patient selection, patient prognosis and methods of treatment of patients based on TIMP-1 levels in the blood, plasma or tumor tissue and the absence or presence of mutations in RAS, in particular KRAS, who are likely to benefit from treatment with an EGFR inhibitor alone or in combination with at least one chemotherapeutic agent. The present invention also provides for a method of treatment of m CRC in patients, which have been identified by the inventive method using the biomarker TIMP-1 and KRAS, who are likely to benefit from the treatment with the EGFR inhibitor cetuximab and at least one chemotherapeutic agent.
展开▼
